Biocon shares jump 8% after likely block deal; here is what is known so far

As per reports, its promoter group entity Mylan likely sold its entire stake in the pharmaceutical firm.

At around 11:12 AM, the stock stood at ₹441.20 per equity share, reflecting a 7.36% increase. It touched a year’s low of ₹331 per unit on August 11, 2025.

The scrip has jumped 7% in the past week and 4% over the month. On a year-to-date basis, it has gained more than 12%.

According to news reports, shares of Biocon changed hands via a block deal in the pre-open session at an average price of ₹400 per share, representing 2.82% of Biocon's total equity.

It is a secondary sale, meaning the shares are being sold ​by an existing investor and Biocon ​will not receive the proceeds, the Reuters report stated.

Recent update

In a regulatory filing dated June 24, Biocon said that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech), via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia.

As part of these contracts, Biocon’s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.

The contracts comprise a three-year agreement valued at approximately MYR 155.27 million for human insulin, along with two 2-year agreements, comprising approximately MYR 18 million for insulin glargine and about MYR 52.5 million for insulin aspart.

“In line with policies indicated in the 13th Malaysia Plan (“RMK-13”) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply,” it said.

Q4 results

The company has posted a 57% fall in its consolidated net profit at ₹199 crore in the fourth quarter of the 2025-26 financial year (Q4 FY26), hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

The company had posted a consolidated net profit of ₹459 crore in the corresponding period of the previous fiscal, Biocon said.

Its revenue from operations in the reporting quarter was at ₹4,516.6 crore, as against ₹4,417 crore in the year-ago period.

Biocon has a total market capitalisation of ₹71,644.12 crore as of July 14, 2026, according to data on the NSE.